Share:
Peer-Reviewed Publication
J Urol2024;211(3):376-383.March 1, 2024Journal Article

Representation Matters: Trust in Digital Health Information Among Black Patients With Prostate Cancer.

Stacy Loeb1,2,3, Tatiana Sanchez Nolasco1,2, Nataliya Byrne1,2, Laura Allen4, Aisha T Langford5, Joseph Ravenell2, Scarlett Lin Gomez4, Samuel L Washington6, Hala T Borno7,8, Derek M Griffith9, Nickole Criner4
1Department of Urology, New York University School of Medicine, New York, New York.
2Department of Population Health, New York University School of Medicine, New York, New York.
3Department of Surgery/Urology, Manhattan Veterans Affairs, New York, New York.
4Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California.
5Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, Michigan.
6Department of Urology, University of California San Francisco, San Francisco, California.
7Department of Medical Oncology, University of California San Francisco, San Francisco, California.
8Trial Library Inc, San Francisco, California.
9Department of Health Management and Policy, Racial Justice Institute and Center for Men's Health Equity, Georgetown University, Washington, Disctrict of Columbia.

Abstract

PURPOSE: Although the majority of US adults obtain health information on the internet, the quality of information about prostate cancer is highly variable. Black adults are underrepresented in online content about prostate cancer despite a higher incidence of and mortality from the disease. The goal of this study was to explore the perspectives of Black patients with prostate cancer on the importa…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.